05.11.2019, Mainz, Germany
SCHOTT teams up with GORE to introduce world’s first silicone-free glass syringe system
Silicone has long been a necessary substance for pre-fillable syringes to help reduce the injection force needed to administer drugs, making the treatment more comfortable for the patient. Yet, silicone may interact with and harm the drug. Pharmaceutical packaging specialist SCHOTT has collaborated with W.L. Gore & Associates to pare GORE ImproJect Plungers with syriQ BioPure® silicone-free1 syringes. Together, we present the first pre-fillable glass syringe (PFS) system that completely eliminates the need for silicone or similar substances. SCHOTT and GORE will highlight this collaboration at CPhl Worldwide in Frankfurt, Nov. 5-7.
International technology group SCHOTT has collaborated with W.L. Gore & Associates, a global material science company, to offer a tested and validated option for the packaging and delivery of complex biologic drugs.
The GORE ImproJect Plunger and syriQ BioPure® silicone-free, prefillable glass syringe provide the only commercial option for a silicone-free, pre-filled syringe to protect sensitive biologics from potential interactions with silicone. Picture: SCHOTT
The collaboration helps meet the needs of the growing market for biologics that are ultra-sensitive to silicone, which applies to an estimated 10 to 15 percent of the global biologics pipeline.
“Biologics stored in pre-fillable glass syringes can come into contact with up to seven components that have the potential to leach and interact,” said Dr. Nicolas Eon, Senior Global Product Manager at SCHOTT. “This product allows a new class of drugs to be manufactured and stored in pre-fillable syringes – a packaging class that offers a great way to save time for clinicians, reduce healthcare costs and improve patient safety.”
syriQ BioPure® silicone-free1 syringes use no silicone inside the syringe barrel. To maintain a consistent gliding force and injection duration over the shelf life of the product on one side, and provide a robust container closure integrity on the other side, great emphasis was given to an accurate geometry. The new syringes are made of FIOLAX® CHR® glass tubing that is 100 percent inspected with the help of a big data process named perfeXion®, ensuring tight dimensions and a high cosmetic quality of each barrel. In addition, syriQ BioPure® silicone-free1 also features ultra-low tungsten residuals as well as low cannula adhesive residuals to lower the extractible profile and reduce risk of container/drug interactions.
The barrels will now be offered with GORE ImproJect silicone-free2 plungers – the industry’s leading silicone-free plunger – to further eliminate the risk of container interaction with sensitive biologics. GORE ImproJect Plungers eliminate the need for silicone as a lubricant in pre-filled syringes. Designed for use in bare-glass (non-siliconized) barrels, these plungers can help to protect complex or sensitive biologics from silicone-induced aggregation and particulation while maintaining consistent injection performance over time.
“Pharmaceutical manufacturers seeking to avoid silicone induced aggregation and sub-visible particles have had to choose vials even when they wanted to offer other delivery options,” said Christiane Gumera, Product Specialist at GORE. “With this collaboration, we’re reducing or eliminating time spent on reformulation when transitioning from vials to pre-filled syringes.”
Together, the GORE ImproJect Plunger and syriQ BioPure® silicone-free1, pre-fillable glass syringes provide the only commercial option for a silicone-free, pre-filled syringe system (plunger and barrel) that protects sensitive biologics from potential interactions with silicone.
1 Silicone oil residuals inside the glass barrel below the detection limit
2 Silicone oil is neither a raw material, nor used in the manufacture of the plungers
SCHOTT is a leading international technology group in the areas of specialty glass, glass-ceramics and related high-tech materials. With over 130 years of experience, the company is an innovative partner to many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT has a global presence with production sites and sales offices in 34 countries. In the 2017/2018 fiscal year, the group generated sales of EUR 2.08 billion with over 15,500 employees. SCHOTT AG has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. This is one of the oldest private and largest science-
promoting foundations in Germany. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.
PR & Communication Manager
PR & Communication Manager
Phone: +49 6131/66-4073